Form DEFA14A enVVeno Medical Corp
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to
Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☒
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material Pursuant to §240.14a-12
|
|
|
|
|
enVVeno Medical Corporation
|
|
|
(Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
N/A
|
|
|
(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)
|
|
Payment of Filing Fee (Check the appropriate box):
|
☒
|
No fee required.
|
||
|
☐
|
Fee paid previously with preliminary materials.
|
||
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
- Introducing Jackery Explorer 100D: The long-term mobile productivity partner redefining portable power stations on the ground, over the road and in the air
- Dr. Ricardo Schwarcz Scholarship for Healthcare Sciences Opens Applications for 2027 Student Researchers and Future Healthcare Professionals
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
